US4428941A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nucleotidic sequence coding the surface antigen of the hepatitis B virus, vector containing said nucleotidic sequence, process allowing the obtention thereof and antigen obtained thereby
Assignee: Institut National de la Santé et de la Recherche Médicale
•
Filing: 1980-08-29
•
Granted: 1984-01-31
•
Expires: 2000-08-29
Abstract
Abstract PCT No. PCT/FR80/00133 Sec. 371 Date Apr. 30, 1981 Sec. 102(e) Date Apr. 29, 1981 PCT Filed Aug. 29, 1980 PCT Pub. No. WO81/00577 PCT Pub. Date Mar. 5, 1981.Nucleic acid of reduced size and vector containing said nucleotidic sequence of which DNA codes an immunogenic peptidic sequence capable of inducing the generation of antibodies to the virus of viral hepatitis B. It comprises totally or partly the sequence of nucleotides represented in FIG. 3A. Application to the production by cloning in a bacterium of an immunogenic protein immunizing against hepatitis B, or application to the obtention of probes for the diagnosis of the presence of Dane particles in a serum.
Inventors
- 👤 Francis Galibert
- 👤 Pierre Tiollais
- 👤 Patrick Charnay
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 13:26
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/005; A; A61; A61K; A61K39/00; A61K39/12; A61K39/29; A61K39/292; C12; C12N; C12N15/00; C12P; C12P21/00; C12P21/02; C12Q; C12Q1/00; C12Q1/70; C12Q1/701; C12Q1/706; A61K38/00; C12N2710/00; C12N2710/00011; C12N2710/10011; C12N2710/10111; C12N2710/10134; C12N2730/00; C12N2730/00011; C12N2730/10011; C12N2730/10111; C12N2730/10122; C12N2730/10134; Y; Y10; Y10S; Y10S530/00; Y10S530/808; Y10S530/82; Y10S530/826; Y10S930/00; Y10S930/01; Y10S930/22; Y10S930/223
Claims Analysis
Total Claims: 16
Claim 1
Independent Claim
19 words
A peptide which comprises the sequence: Alanine-Glutamine-Glycine-Threonine-Serine, wherein the alanine end is N-terminal and the serine end is C-terminal.
Claim 2
Dependent Claim
19 words
A peptide which comprises the sequence: Alanine-Glutamine-Glycine-Threonine-Serine, wherein the alanine end is N-terminal and the serine end is C-terminal.
Claim 3
Dependent Claim
19 words
A peptide which comprises the sequence: Threonine-Alanine-Glutamine-Glycine-Threonine-Serine, wherein the threonine end is N-terminal and the serine end is C-terminal.
Claim 4
Dependent Claim
19 words
A peptide which comprises the sequence: Threonine-Alanine-Glutamine-Glycine-Threonine-Serine, wherein the threonine end is N-terminal and the serine end is C-terminal.
Claim 5
Dependent Claim
19 words
A peptide which comprises the sequence: Threonine-Threonine-Alanine-Glutamine-Glycine-Threonine-Serine, wherein the threonine end is N-terminal and the serine end is C-terminal.
Claim 6
Dependent Claim
19 words
A peptide which comprises the sequence: Threonine-Threonine-Alanine-Glutamine-Glycine-Threonine-Serine, wherein the threonine end is N-terminal and the serine end is C-terminal.
Claim 7
Dependent Claim
22 words
A peptide which comprises the amino acid sequence of FIG. 5 starting with serine (number 113) and ending with tryptophan (number 165).
Claim 8
Dependent Claim
22 words
A peptide which comprises the amino acid sequence of FIG. 5 starting with serine (number 113) and ending with tryptophan (number 165).
Claim 9
Dependent Claim
15 words
The peptide of claim 4 which comprises within the peptide the amino acid sequence: Alanine-Glutamine-Glycine-Threonine-Serine.
Claim 10
Dependent Claim
15 words
The peptide of claim 3 which comprises within the peptide the amino acid sequence: Threonine-Alanine-Glutamine-Glycine-Threonine-Serine.
Claim 11
Dependent Claim
15 words
The peptide of claim 4 which comprises within the peptide the amino acid sequence: Threonine-Threonine-Alanine-Glutamine-Glycine-Threonine-Serine.
Claim 12
Dependent Claim
47 words
An immunogenic peptide sequence which comprises the amino acids shown in FIGS. 3A, 3B, and 3C numbering not less than 5 amino acids and not more than 226 amino acids which peptide induces in vivo the production of active antibodies with respect to the hepatitis B virus.
Claim 13
Dependent Claim
47 words
An immunogenic peptide sequence which comprises the amino acids shown in FIGS. 3A, 3B, and 3C numbering not less than 5 amino acids and not more than 226 amino acids which peptide induces in vivo the production of active antibodies with respect to the hepatitis B virus.
Claim 14
Dependent Claim
44 words
The immunogenic peptide sequence which comprises the amino acids shown in FIG. 6 numbering not less than 5 amino acids and not more than 53 amino acids, which peptide induces in vivo the production of active antibodies with respect to the hepatitis B virus.
Claim 15
Dependent Claim
44 words
The immunogenic peptide sequence which comprises the amino acids shown in FIG. 6 numbering not less than 5 amino acids and not more than 53 amino acids, which peptide induces in vivo the production of active antibodies with respect to the hepatitis B virus.
Claim 16
Dependent Claim
36 words
A pharmaceutical composition comprising an effective amount of the peptides of claims 1, 2, 3, 4, 5, 6 or 7, wherein composition induces in vivo production of antibodies, the hepatitus B-viruis, and a pharmaceutically acceptable carrier.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-01-30 | 1987-08-01 | 1988-01-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-01-30 | 1991-08-01 | 1992-01-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-01-30 | 1995-08-01 | 1996-01-31 | $7700.00 | Window Closed / Lapsed |